– UK, Cambridge – Xaar plc (LON: XAR), the leading inkjet printing technology group, announced the appointment of Dr. Inken Braunschmidt (Ph.D.) to its Board as Independent Non-Executive Director with effect from 1 June 2024.
Dr. Inken Braunschmidt will join the Audit, Remuneration, and Nomination Committees.
Richard Amos is appointed as Senior Independent Director effective on 1 July 2024, to replace Alison Littley who will step down from the Board on 30 June 2024.
About Dr. Inken Braunschmidt
Inken Braunschmidt is currently a non-executive director of James Fisher and Sons plc, listed on the London Stock Exchange, and Chair of its Remuneration Committee as well as a member of the Audit and Nomination Committees. She was CIDO and a member of the Executive Board of Halma plc until 2023. Before joining Halma plc in 2017, Inken spent 13 years at RWE AG, the German energy giant, and its renewables subsidiaryInnogyy SE, where she held various international leadership roles focusing on strategy, innovation, digital transformation,n and change management.
Dr. Inken Braunschmidt studied Business Administration, Innovation & Technology Management at Kiel University and did her PhD thesis in Technology Management. Inken is a member of the Digital Programme Board of the Royal Academy of Engineering.
Andrew Herbert, Chairman, commented: “We are delighted to welcome Inken to the Board and her expertise and experience in international electronic engineering and digital innovation and transformation are very relevant to the opportunities and challenges that face Xaar. I would like to thank Alison for her contribution and commitment to the Board of Xaar as a director since 2020 and wish her the very best for the future.”
For more: https://www.xaar.com/en/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
